What do systematic reviews say?

Small‐volume residual disease (SVRD) (< 1 cm) vs NMRD

It is very uncertain whether small‐volume residual disease (SVRD) (< 1 cm) changes overall survival: Median length of compared with NMRD (very low certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 2.09 [1.2, 3.6]
  1 study · 310 participants
  Very low

Small‐volume residual disease (SVRD) (< 1 cm) vs NMRD

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 322 participants
  Very low

Small‐volume residual disease (SVRD) (< 1 cm) vs NMRD

Small‐volume residual disease (SVRD) < 1 cm probably leads to higher overall survival: Median length of compared with NMRD (moderate certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 2.03 [1.8, 2.29]
  17 studies · 9404 participants
  Moderate

Small‐volume residual disease (SVRD) (< 1 cm) vs NMRD

Small‐volume residual disease (SVRD) < 1 cm probably leads to higher progression‐free survival: Median length of compared with NMRD (moderate certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 1.88 [1.63, 2.16]
  10 studies · 6596 participants
  Moderate

Large‐volume residual disease (LVRD) > 1 cm vs small‐volume residual disease (SVRD) < 1 cm

It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes overall survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (very low certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 1.6 [1.21, 2.11]
  6 studies · 1572 participants
  Very low

Large‐volume residual disease (LVRD) > 1 cm vs small‐volume residual disease (SVRD) < 1 cm

It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes progression‐free survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (very low certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 1.76 [1.23, 2.52]
  4 studies · 1145 participants
  Very low

Large‐volume residual disease (LVRD) > 1 cm vs small‐volume residual disease (SVRD) < 1 cm

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher overall survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (moderate certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 1.22 [1.13, 1.32]
  5 studies · 6000 participants
  Moderate

Large‐volume residual disease (LVRD) > 1 cm vs small‐volume residual disease (SVRD) < 1 cm

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher progression‐free survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (moderate certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 1.3 [1.08, 1.56]
  2 studies · 3402 participants
  Moderate